Stock·NYSE·Technology
Fabrinet (FN)
- Market cap
- $13.03B
- P/E
- 27.86
- Dividend yield
- 0.00%
- Street target
- $750.00median of 9 analysts
- 52-week range
- $362.64 $748.89
The short version
Where FN stands today, in four lines, and what CleaRank Financial AI makes of it.
FN at a glance
Fabrinet (FN): Hold, 58/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($442.00 and $530.69).
- Earnings FN beat estimates in 7 of its last 7 quarters, yet fell the next day after 6 of those beats.
- Insiders Insiders sold $43.7M and made no open-market purchases over the last 18 months.
- Valuation P/E of 27.9 against 35.1 for the Technology sector: a discount to peers (-21%).
Figures as of October 18, 2026.
CleaRank Financial AI
CleaRank rates Fabrinet (FN) Hold, with a model score of 58/100.
Valuation lifts the score most: the P/E of 27.86 is 20.6% below the sector median (a discount to peers) and the P/S of 2.81 is 63.0% below the sector median. The trend holds it back most: the price is 31.50% below its 200-day average and 17.76% below its 50-day average, and the 50-day average is 16.71% below the 200-day. The 50-day average stands at $442.00 and the 200-day at $530.69. Over the past year the price fell 11.87%.
Only on CleaRank
Figures we compute ourselves from FN's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
0/4Price above its 50-day average ›
The price of $363.51 is 17.8% below the 50-day simple moving average of $442.00.Price above its 200-day average ›
The price is 31.5% below the 200-day simple moving average of $530.69.50-day average above the 200-day ›
The 50-day average ($442.00) is 16.7% below the 200-day average ($530.69), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 0% of its 52-week range, between $362.64 and $748.89.
FN share price
Pick a period: each tab shows how far FN has moved over it, to the last close.
Today's trading
Where FN sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/4P/E below the sector median ›
The trailing P/E of 27.86 is 20.6% below the Technology median of 35.1.P/S below the sector median ›
The price-to-sales ratio of 2.81 is 63.1% below the sector median of 7.6.Profitable over the last 12 months ›
Net income over the last 12 months was $473.0M on revenue of $4.6B, a net margin of 10.2%.Beat estimates in most recent reports ›
FN beat the EPS estimate in 7 of its last 7 reports.
Key statistics
The headline figures for FN.
As of October 18, 2026, FN trades at $363.51, with a market value of $13.03B and a P/E ratio of 27.86.
What the numbers say
CleaRank Financial AI's reading of FN's valuation, growth and risks.
Priced at 27.86 times trailing earnings, Fabrinet (FN) sits 20.6% below the Technology median of 35.1, a P/E the peer comparison on this page rates as a discount to peers. The price-to-sales ratio of 2.81 sits 63.0% below the sector median of 7.6. FN has a market capitalisation of $13.0B and trailing earnings of $13.05 a share.
FN is growing faster than its sector, with revenue up 44.60% in the latest year against a sector median of 24.2%. The business converts sales into profit: a net margin of 10.19% and an operating margin of 10.23%. Its return on equity of 21.33% sits above the sector median of 13.4%. On the balance sheet, debt-to-equity is 0.00.
FN's latest report, released on August 17, 2026, came in ahead of expectations: EPS of $4.10 a share compared with a $3.81 estimate, a beat of 7.61%. The share price nonetheless dropped 19.38% in the first session after the report.
FN has beaten the EPS estimate in all 7 of its recent reports, though the stock still fell in the first session after 6 of those 7 beats. The largest of the earlier reactions came after the February 2, 2026 report, which beat the estimate by 3.38% while the stock fell 10.22%. The consensus EPS estimate stands at $18.20 for this fiscal year and $21.79 for next, growth of 29.1% for the current year.
Normal swings for FN run at about 4.03% a day. Until the price regains its moving averages, the trend works against holders. The price is 51.46% below its 52-week high of $748.89. Insiders sold $43.7M over the last 18 months and bought none on the open market, though sales of this kind are often planned in advance and say less than purchases would.
FN against the Technology sector
How FN compares with the median Technology stock CleaRank tracks.
Price to earnings vs sector: FN trades at a notable discount to sector peers (-21%), which may indicate undervaluation or specific company headwinds.
Return vs XLK: Since May 6, 2025, FN has gained 77.5% against a gain of 71.7% for XLK.
Performance against XLK
FN and the Technology sector fund over the same days.
Revenue and earnings
How much FN sells, and how much of it becomes profit.
Revenue growth: Revenue grew 18.6% in FY2025 to $3.4B, from $2.9B a year earlier.
Profit margin: The net margin was 9.7% in FY2025, down from 10.3% the year before.
Profitable: FN earned $333M in FY2025.
Earnings reality check
Did FN beat what analysts expected, and how did the stock react?
Earnings record: FN beat the analyst estimate in 7 of the last 7 quarters.
Market reaction: The stock fell in the first session after 6 of those 7 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 17, 2026after close | $3.81 | $4.10 | +7.61% | -19.38% | -29.64% |
| May 4, 2026after close | $3.56 | $3.72 | +4.49% | -8.01% | -9.51% |
| Feb 2, 2026after close | $3.25 | $3.36 | +3.38% | -10.22% | +0.46% |
| Nov 3, 2025after close | $2.82 | $2.92 | +3.55% | +3.75% | +5.47% |
| Aug 18, 2025after close | $2.63 | $2.65 | +0.76% | -12.81% | -4.54% |
| May 5, 2025after close | $2.47 | $2.52 | +2.02% | -7.27% | -2.49% |
| Feb 3, 2025after close | $2.49 | $2.61 | +4.82% | -8.19% | -6.52% |
As of October 18, 2026, FN has beaten the analyst EPS estimate in 7 of its last 7 reported quarters and fell in the first trading session after 6 of those beats; its latest report, on August 17, 2026, came in 7.61% above the estimate and the stock moved -19.38% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 34.0, showing bearish momentum without being oversold.RSI above 50 ›
An RSI of 34.0 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of FN
The score, the reasoning behind it, and what could move the price next.
FN is trading in a downtrend. The stock is priced at $363.51, which leaves it 17.76% below its 50-day average of $442.00 and 31.50% below its 200-day average of $530.69. Near the bottom of its 52-week range, the price is 0.24% above the low of $362.64 and 51.46% below the high of $748.89.
The 14-day RSI of 34.0 is in the bearish zone, above the oversold line, and the MACD line is negative. The record is negative across every period shown: the price fell 24.01% over the past three months, fell 47.31% over the past six months and fell 11.87% over the past year.
Earnings beat ›
The August 17, 2026 report beat the EPS estimate by 7.61%, and the share price fell 19.38% in the first session after it.
Source: Earnings report, August 17, 2026
Rating reaffirmed ›
Rosenblatt kept its Buy rating on August 20, 2026.
Source: Analyst action, Rosenblatt, August 20, 2026
- Two levels matter most: the 20-day EMA at $428.20, which sits above the price, and the 52-week low at $362.64, which sits below it.
- A 14-day RSI of 34.0 lands in the bearish zone, and the MACD line is negative. Readings above 70 or below 30 would signal stretched momentum.
- FN fell 19.38% in the first session after its August 17, 2026 report, even though it has beaten estimates in 7 of the last 7 reports.
The trend is down because FN sits below its 50-day and 200-day moving averages ($442.00 and $530.69). Reclaiming the 50-day average would be the first sign of repair. Above the price, the first level to watch is the 20-day EMA at $428.20.
The next level below the price is the 52-week low at $362.64. With the RSI in the bearish zone, momentum still leans toward lower prices.
Technical indicators
Momentum and trend for FN, from its daily closes.
As of October 18, 2026, with FN at $363.51, its 14-day RSI is 34.0 (showing bearish momentum without being oversold), its 50-day simple moving average is $442.00 and its 200-day is $530.69.
Calculated by CleaRank on daily closes as of October 18, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What FN moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 18, 2026, FN's 1-year correlation of daily returns is +0.51 with S&P 500 (SPY), +0.58 with Nasdaq 100 (QQQ), +0.20 with Bitcoin (BTC) and +0.09 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
7 of 9 analysts rate it a buy or strong buy, 2 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $750.00 is 106.3% above the price.More buy ratings than three months ago ›
7 of 9 rate it a buy now, against 7 of 9 three months ago.
FN Wall Street View
12-month price targets
The price, $363.51, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 20, 2026 | Rosenblatt | Maintains | Buy |
| Aug 18, 2026 | JP Morgan | Maintains | Neutral |
| Aug 18, 2026 | Barclays | Maintains | Overweight |
| Aug 18, 2026 | Rosenblatt | Maintains | Buy |
| Aug 18, 2026 | Needham | Reiterates | Buy |
| Jul 22, 2026 | Needham | Maintains | Buy |
As of October 18, 2026, 9 Wall Street analysts cover FN: 7 rate it a buy or strong buy, 2 a hold and 0 a sell or strong sell. Their 12-month price targets range from $598.00 to $850.00, with a median of $750.00, 106.3% above the price of $363.51.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
FN trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
FN moves about 4.0% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much FN tends to move, against the market and on its own.
The long record
FN's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 4.03% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 51.3%, from May 2026 to October 2026; the price is still 51.3% below that peak.Most 1-year holds ended higher ›
84% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $86,018, against $41,793 in the S&P 500 (SPY).
FN Drawdowns & Recovery
As of October 18, 2026, FN's worst peak-to-trough fall over the last 10 years with dividends reinvested was -51.3% (May 2026 to October 2026); it is still 51.3% below that peak, and 84% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into FN in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: FN beat the S&P 500 over this period: $86,018 against $41,793.
A $10,000 investment in FN in October 2016 would be worth about $86,018 today with dividends reinvested, compared with about $41,793 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to FN, and which have not.
Strongest month, June: an average of +7.58%, up in 5 of 10 years.
Weakest month, September: an average of -3.56%, up in 3 of 10 years.
This month, October: has averaged +4.87%, up in 6 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, FN's strongest calendar month has been June (average +7.58%, up in 5 of 10 years) and its weakest September (average -3.56%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in FN, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in FN today could grow to about $27,879 by 2036 in the base case, with a 90th-percentile outcome near $209,877 and a 10th-percentile outcome around $3,703. Projections are statistical simulations, not guarantees.
FN Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $548 for FN by 2030 in the base case, from $364 today (1.5x over 4 years). The 10th-percentile path ends near $153. These are outcomes of a Monte Carlo simulation run on FN's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $213 | $403 | $763 | |
| 2028 | $181 | $446 | $1,101 | |
| 2029 | $164 | $494 | $1,494 | |
| 2030 | $153 | $548 | $1,964 | |
| 2031 | $146 | $607 | $2,530 |
Method: a lognormal simulation of FN's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. FN is highly volatile, so its upside column reaches an extreme multiple; treat it as a statistical tail, not an expectation.
Insider trading
What the people running the company have bought and sold.
FN insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought FN shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 18, 2026, FN insiders reported 19 open-market sales worth $43.7M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 3, 2026 | Edward T Archer
Officer
|
Sell | 2.5K | $964.8K |
| Aug 20, 2026 | Edward T Archer
Officer
|
Grant | 2.0K | - |
| Aug 20, 2026 | Harpal S. Gill
President
|
Grant | 4.3K | - |
| Aug 20, 2026 | Seamus Grady
Chief Executive Officer
|
Grant | 22.5K | - |
| Aug 20, 2026 | Csaba Sverha
Chief Financial Officer
|
Grant | 2.7K | - |
| Aug 11, 2026 | Edward T Archer
Officer
|
Grant | 6.0K | - |
| Aug 11, 2026 | Harpal S. Gill
President
|
Grant | 12.8K | - |
| Aug 11, 2026 | Seamus Grady
Chief Executive Officer
|
Grant | 20.0K | - |
| Aug 11, 2026 | Csaba Sverha
Chief Financial Officer
|
Grant | 7.6K | - |
| May 22, 2026 | Homa Bahrami
Director
|
Sell | 2.5K | $1.8M |
| Feb 26, 2026 | Thomas F. Kelly
Director
|
Grant | 150 | - |
| Feb 25, 2026 | Thomas F. Kelly
Director
|
Sell | 1.9K | $1.2M |
| Dec 11, 2025 | Forbes I J Alexander
Director
|
Grant | 417 | - |
| Dec 11, 2025 | Homa Bahrami
Director
|
Grant | 417 | - |
| Dec 11, 2025 | Caroline Dowling
Director
|
Grant | 417 | - |
| Dec 11, 2025 | Thomas F. Kelly
Director
|
Grant | 417 | - |
| Dec 11, 2025 | Frank H Levinson
Director
|
Grant | 417 | - |
| Dec 5, 2025 | Darlene Knight
Director
|
Sell | 500 | $241.1K |
| Dec 5, 2025 | Thomas F. Kelly
Director
|
Grant | 25 | - |
| Dec 4, 2025 | Thomas F. Kelly
Director
|
Sell | 2.2K | $1.0M |
| Dec 4, 2025 | Darlene Knight
Director
|
Sell | 500 | $236.0K |
| Dec 3, 2025 | Rollance E. Olson
Director
|
Grant | 70 | - |
| Dec 1, 2025 | Homa Bahrami
Director
|
Sell | 3.5K | $1.6M |
| Nov 26, 2025 | Seamus Grady
Chief Executive Officer
|
Sell | 22.5K | $10.0M |
| Oct 13, 2025 | Caroline Dowling
Director
|
Grant | 93 | - |
| Sep 5, 2025 | Darlene Knight
Director
|
Sell | 479 | $175.3K |
| Sep 5, 2025 | Thomas F. Kelly
Director
|
Grant | 480 | - |
| Sep 4, 2025 | Harpal S. Gill
President
|
Sell | 14.2K | $5.0M |
| Sep 4, 2025 | Edward T Archer
Officer
|
Sell | 3.3K | $1.2M |
| Sep 2, 2025 | Rollance E. Olson
Director
|
Sell | 9.0K | $3.0M |
| Aug 29, 2025 | Edward T Archer
Officer
|
Sell | 3.2K | $1.1M |
| Aug 28, 2025 | Csaba Sverha
Chief Financial Officer
|
Sell | 13.0K | $4.5M |
| Aug 27, 2025 | Seamus Grady
Chief Executive Officer
|
Sell | 9.5K | $3.1M |
| Aug 27, 2025 | Darlene Knight
Director
|
Sell | 1.2K | $402.2K |
| Aug 25, 2025 | Csaba Sverha
Chief Financial Officer
|
Sell | 10.0K | $3.1M |
| Aug 21, 2025 | Edward T Archer
Officer
|
Grant | 3.0K | - |
| Aug 21, 2025 | Harpal S. Gill
President
|
Grant | 6.2K | - |
| Aug 21, 2025 | Seamus Grady
Chief Executive Officer
|
Grant | 11.4K | - |
| Aug 21, 2025 | Csaba Sverha
Chief Financial Officer
|
Grant | 3.8K | - |
| Aug 12, 2025 | Edward T Archer
Officer
|
Grant | 9.4K | - |
| Aug 12, 2025 | Harpal S. Gill
President
|
Grant | 20.5K | - |
| Aug 12, 2025 | Seamus Grady
Chief Executive Officer
|
Grant | 32.7K | - |
| Aug 12, 2025 | Csaba Sverha
Chief Financial Officer
|
Grant | 11.3K | - |
| Jun 4, 2025 | Harpal S. Gill
Chief Executive Officer
|
Sell | 18.7K | $4.5M |
| May 13, 2025 | Rollance E. Olson
Director
|
Sell | 2.5K | $559.9K |
Source: TwelveData, from reported insider filings
Questions people ask
Answered from the figures on this page, as of October 18, 2026.